| (AstraZeneca) D9078C00001 / PACIFIC-9 | A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy | Dr Rosalyn Juergens | Open to recruitment | NCT05221840 |
| (CCTG) BR.36 | A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with Non-Small Cell Lung Cancer | Dr Rosalyn Juergens | Suspended/On hold | NCT04093167 |
| (CCTG) BRC.8/ SWOG S1827/ MAVERICK | MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) | Dr Anand Swaminath | Suspended/On hold | NCT04155034 |
| (HHS) LINNEARRE I | Phase I study of neo-adjuvant stereotactic body radiotherapy (SBRT) in operable patients with borderline resectable locally advanced non-small cell lung cancer (NSCLC) | Dr Theos Tsakiridis | Open to recruitment | NCT02433574 |
| (LHRI) OCELOT / ESR-18-14132 | OCELOT – Osimertinib then Chemotherapy in EGFR-mutated Lung cancer with Osimertinib Third-line rechallenge | Dr Rosalyn Juergens | Open to recruitment | NCT04335292 |
| (Merck) MK-7684A-003 | A Phase 3, Multi-center, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Co-formulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants with PD-L1 Positive (TPS ≥1%) Metastatic Non-Small Cell Lung Cancer | Dr Rosalyn Juergens | Open to recruitment | NCT04738487 |
| (Pharma Mar) PM1183-C-008-21 / LAGOON | A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer (SCLC) Patients | Dr Peter Ellis | Suspended/On hold | NCT05153239 |
| (SignalChem) SLC-391-102 / SKYLITE | A Single-Arm, Open-Label, Phase 1b/2 Study of SLC-391, an AXL Inhibitor, in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Dr Rosalyn Juergens | Open to recruitment | NCT05860296 |
Find a Trial
Contact Us